Chlamydia Market size was valued at USD 3.07 billion in 2023 and is set to cross USD 8.97 billion by 2036, expanding at more than 8.6% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of chlamydia is evaluated at USD 3.28 billion. The growth of the market can be attributed to the increasing prevalence chlamydia and other sexually transmitted diseases, and rise in demand for screening of the disease among people all around the world. According to the World Health Organization, each year, there are an estimated 376 million new infections with 1 of 4 STIs: chlamydia, gonorrhea, syphilis and trichomoniasis. Also, more than 1 million sexually transmitted infections (STIs) are acquired every day worldwide. Along with these, growing number of government initiatives and free diagnostic camps for spreading awareness about sexually transmitted infections is also predicted to be a significant factor driving market growth in the near future. Furthermore, favorable reimbursement policies for companies are evaluated to give impetus to research and development activities associated with the development of novel drugs, which in turn is projected to offer lucrative opportunities for market growth in the forthcoming years.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
8.6% |
|
Base Year Market Size (2023) |
USD 3.07 billion |
|
Forecast Year Market Size (2036) |
USD 8.97 billion |
|
Regional Scope |
|
The market is segmented by test type into culture tests, nucleic acid amplification test (NAAT), direct fluorescent antibody test, serology tests, and others, out of which, the nucleic acid amplification test (NAAT) segment is anticipated to hold the largest share in the global Chlamydia market. This can be accounted to the high accuracy of the test in screening the disease. Apart from these, NAATs allow screening of large number of males and females using self-collected vaginal swabs or using urine without the requirement of a pelvic examination. Additionally, on the basis of route of administration, the oral segment is assessed to acquire the largest share over the forecast period owing to the non-invasive nature, ease of convenience, and cost-effectiveness of this type of route for drug administration.
Our in-depth analysis of the global Chlamydia market includes the following segments:
|
By Test Type |
|
|
By Route of Administration |
|
|
By End User
|
|
On the basis of geographical analysis, the global Chlamydia market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and the Middle East & Africa region. Asia Pacific industry is expected to account for largest revenue share by 2036, on account of growing demand for medical screening and burgeoning need for raising awareness about STIs. In addition, rapid growth of biopharmaceutical industry and rising government support for improving the healthcare infrastructure are also anticipated to drive the region’s market growth in the future. Moreover, the market in North America is projected to grab the largest share during the forecast period ascribing to the high adoption rate of medical screening, high prevalence of STDs, and presence of a large number of pharmaceutical and biopharmaceutical companies in the region. As per the Centers for Disease Control and Prevention, in 2019, a total of 1,808,703 cases of Chlamydia trachomatis infection were reported, making it the most common notifiable condition in the United States for that year.
October 2019- GSK began the phase III clinical program for new chemical class of antibiotic, gepotidacin, in patients with uncomplicated urinary tract infection and STDs.
August 2019- Statens Serum Institut, completed the clinical phase 1 trial for first-generation vaccine candidate (CTH522), which is aimed to provide a preventive therapy for chlamydia infection.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?